Bali to Host 13th DCVMN Conference

Admin | Rabu, 24 Oktober 2012

Indonesian vaccinemaker Bio Farma is to host the 13th Annual General Meeting of Developing Countries Vaccine Manufacturers Network (DCVMN) in Bali, on October 31November 2, 2012. Bio Farma President Director Iskandar said on Tuesday that DCVMN is a strategic alliance among developing countries' vaccine manufacturers. Indonesia is a founding member of the vaccine network with a membership of 14 countries. In total, there are currently 37 vaccinemaking organizations and company members in the 14 DCVMN member countries. Iskandar says, since its establishment in Bandung in 1999, the network has achieved numerous milestones particularly in providing quality and affordable vaccines accessible to developing countries populations. The objective of 13th DCVMN General Meeting refers to the specific purpose of striving to increase availability and to improve the quality of vaccines produced in the developing countries. Bio Farma had assumed the position of first president of the group. The network strives to promote the consistent and sustainable supply of quality vaccines at an affordable price and combat infectious diseases, especially those from the developing world, by strengthening the capacity of vaccine related product manufactures. It also encourages research and development efforts to meet the need for vaccines, and fosters production and delivery of high quality vaccines and other health technologies effectively on a longterm basis for national immunization programs. Bio Farma President Director Iskandar also says Bio Farma is the only vaccine manufacturer from Indonesia who strives to become a center for research and development of vaccines and serve as a partner to research new vaccines for developing countries. Member countries of the DCVMN are Argentina, Bangladesh, Brazil, Cuba, Egypt, India, Indonesia, Iran, Mexico, Republic of China, Republic of Korea, South Africa, Thailand and Vietnam. Member companies and organizations of DCVMN are Beijing Minhai Biotechnology, Bharat Biotech International Limited, Biological E. Limited, BioManguinhos Institute of Technology on Immunobiologicals, BioNetAsia Co., Ltd., Cadila Pharmaceuticals Limited, Center for Genetic engineering and Biotechnology, Chengda Liaoning, and China National Biotec Group (CNBG). Other members include EuBiologics, Finlay Institute, Haffkine, Hualan Bio, Incepta Ltd., Indian Immunologicals Limited, Institute of Vaccines and Medical Biologicals, Instituto Butantan, National Administration of Laboratories and Institute of Health ANLIS "Dr. Carlos G. Malbran." Also represented are Panacea Biotec Ltd, Pasteur Institute of Iran, PT Bio Farma (Persero), Queen Saovabha Memorial Institute, Razi Vaccine & Serum Research Institute, Serum Institute of India Ltd, Sinergium, Sinovac Biotech Ltd., SK Chemicals, Biovac Institute, Company for Vaccine and Biological Production No.1 Vabiotech, the Government Pharmaceutical Organization, the Holding Company for Biological Products & Vaccines (VACSERA), Tiantan, Walvax and Xiamen Innovax Biotech. About DCVMN The Developing Countries Vaccine Manufacturers Network (DCVMN) aims to protect people against known and emerging infectious diseases globally by increasing the availability and enhancing the quality of vaccines produced in emerging countries. DCVMN works to strengthen vaccine manufacturers through the provision of information programs and professional training on technical improvements, research in vaccine production, encouraging technology transfer initiatives, and educating the public about the availability of safe and effective vaccines, from developing world manufacturers and related programs. The purposes of the Association are carried through the provision of technical assistance, training and research in vaccine production, informational programmes aimed at educating the public about the availability of safe and effective vaccines from developing world manufactures, and related workshops. For more information, please visit sumber :

Tagged :